(Q39564433)

13 September 2017

title

Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy (English)

1 reference

13 September 2017

1 reference

12

1 reference

13 September 2017

13

1 reference

13 September 2017

Francesca Bianchi

5

0 references

Veronica Huber

Veronica Huber

2

0 references

Elisabetta Venturelli

Elisabetta Venturelli

4

0 references

Daniele Morelli

Daniele Morelli

7

0 references

Serenella M Pupa

Serenella M Pupa

14

0 references

author name string

Valentina Ciravolo

1

1 reference

13 September 2017

Gaia C Ghedini

3

1 reference

13 September 2017

Manuela Campiglio

6

1 reference

13 September 2017

Antonello Villa

8

1 reference

13 September 2017

Pamela Della Mina

9

1 reference

13 September 2017

Sylvie Menard

10

1 reference

13 September 2017

Paola Filipazzi

11

1 reference

13 September 2017

publication date

1 February 2012

1 reference

Journal of Cellular Physiology

13 September 2017

published in

1 reference

13 September 2017

volume

227

1 reference

13 September 2017

issue

2

1 reference

13 September 2017

page(s)

658-667

1 reference

Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.

13 September 2017

cites work

1 reference

Microvesicles: messengers and mediators of tumor progression

21 January 2018

1 reference

Malignant effusions and immunogenic tumour-derived exosomes

21 January 2018

1 reference

Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.

21 January 2018

1 reference

Proteomic analysis of exosomes isolated from human malignant pleural effusions

21 January 2018

1 reference

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

Exosomal-like vesicles are present in human blood plasma

21 January 2018

1 reference

Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].

21 January 2018

1 reference

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.

21 January 2018

1 reference

Breast cancer-specific mutations in CK1epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration.

21 January 2018

1 reference

Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility

21 January 2018

1 reference

Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer

21 January 2018

1 reference

Tumour-released exosomes and their implications in cancer immunity.

21 January 2018

1 reference

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer

21 January 2018

1 reference

High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients

21 January 2018

1 reference

Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs

21 January 2018

1 reference

Lapatinib and breast cancer: current indications and outlook for the future

21 January 2018

1 reference

Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens

21 January 2018

1 reference

A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis

21 January 2018

1 reference

Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion.

21 January 2018

1 reference

Exosome release is regulated by a calcium-dependent mechanism in K562 cells

21 January 2018

1 reference

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg).

21 January 2018

1 reference

Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification.

21 January 2018

1 reference

HER2 as a target for breast cancer therapy.

21 January 2018

1 reference

Membrane vesicles as conveyors of immune responses

21 January 2018

1 reference

Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes

21 January 2018

1 reference

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCP.22773

1 reference

release_r3liuqglrnc7plnsng4rvsluiq

13 September 2017

Fatcat ID

0 references

1 reference